{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:16:14Z","timestamp":1775301374167,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Incidence of drug-drug interactions (DDIs) has been widely reported; however, such reports in pediatric oncology patients still remain scarce. We studied frequency and demographic correlates of moderate and major DDIs at a pediatric oncology ward in Isfahan, Iran. All pediatric oncology patients admitted to the Omid hospital during a 6-month period (2017) who received at least 2 anticancer or non-anticancer drugs concomitantly were included in our study. Potential DDIs between anticancer and non-anticancer drugs during hospitalization was identified using Lexi-Interact on-line software. We detected 194 DDIs with moderate or major severity for our included 115 patients. Mechanistically, most of DDIs (56.4%) were pharmacodynamic. Systematic use of corticosteroids (82.0%), antimetabolites (77.0%), and antiemetic drugs (69.5%) were the most frequent medication classes responsible for detected DDIs. The interaction between aminoglycosides and the third generation cephalosporins was the most common (13.9%) non-anticancer DDI. The only identified interaction between 2 anticancer drugs was doxorubicin with cyclophosphamide. Age, sex, and the number of administered medications were associated with DDIs. Potential moderate or major DDIs occur frequently among pediatric cancer patients. More studies are needed to assess clinical and economic implications of DDIs in pediatric oncology patients.<\/jats:p>","DOI":"10.1097\/mph.0000000000001346","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T13:47:16Z","timestamp":1544190436000},"page":"e146-e151","source":"Crossref","is-referenced-by-count":10,"title":["Potential Drug-drug Interactions at a Referral Pediatric Oncology Ward in Iran: A Cross-sectional Study"],"prefix":"10.1097","volume":"41","author":[{"given":"Faezeh","family":"Tavousi","sequence":"first","affiliation":[{"name":"Clinical Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Hematology-Oncology Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Darakhshandeh","sequence":"additional","affiliation":[{"name":"Hematology-Oncology Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Moghaddas","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00228-007-0436-8","article-title":"Improvement in the handling of drug-drug interactions","volume":"64","author":"Fuhr","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nrc1887","article-title":"Drug interactions in cancer therapy","volume":"6","author":"Scripture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/157016310793180549","article-title":"Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions","volume":"7","author":"Lu","year":"2010","journal-title":"Curr Drug Discov Technol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5414\/CPP38504","article-title":"Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use","volume":"38","author":"K\u00f6hler","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(04)01528-1","article-title":"Drug interactions in oncology","volume":"5","author":"Beijnen","year":"2004","journal-title":"Lancet Oncol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00228-002-0557-z","article-title":"Potential drug-drug interactions in the medication of medical patients at hospital discharge","volume":"58","author":"Egger","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00228-005-0978-6","article-title":"Drug-drug interactions among recently hospitalised patients\u2014frequent but mostly clinically insignificant","volume":"6","author":"Glintborg","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0735-6757(96)90147-3","article-title":"Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population","volume":"14","author":"Goldberg","year":"1996","journal-title":"Am J Emerg Med"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0196-0644(05)81897-9","article-title":"Prospective evaluation of adverse drug interactions in the emergency department","volume":"21","author":"Herr","year":"1992","journal-title":"Ann Emerg Med"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/2008-2231-22-52","article-title":"Drug-drug interactions in inpatient and outpatient settings in Iran: a systematic review of the literature","volume":"22","author":"Nabovati","year":"2014","journal-title":"DARU J Pharm Sci"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/annonc\/mdp369","article-title":"Drug interactions in oncology: how common are they?","volume":"20","author":"Riechelmann","year":"2009","journal-title":"Ann Oncol"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s00280-013-2162-5","article-title":"Potential drug\u2013drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study","volume":"71","author":"Hadjibabaie","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00280-004-0998-4","article-title":"Potential for drug interactions in hospitalized cancer patients","volume":"56","author":"Riechelmann","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.apjtb.2016.04.002","article-title":"Potential drug-drug interactions in pediatric wards of Gondar University Hospital, Ethiopia: a cross sectional study","volume":"6","author":"Getachew","year":"2016","journal-title":"Asian Pac J Trop Biomed"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s11096-010-9445-2","article-title":"Evaluation of three brands of drug interaction software for use in intensive care units","volume":"32","author":"Reis","year":"2010","journal-title":"Pharm World Sci"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11096-008-9191-x","article-title":"Evaluation of frequently used drug interaction screening programs","volume":"30","author":"Vonbach","year":"2008","journal-title":"Pharm World Sci"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/s11096-014-0011-1","article-title":"Pharmacoepidemiological study of drug-drug interactions in onco-hematological pediatric patients","volume":"36","author":"de Palencia Espinosa","year":"2014","journal-title":"Int J Clin Pharm"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/0022-3859.85207","article-title":"A study of drug-drug interactions in cancer patients of a south Indian tertiary care teaching hospital","volume":"57","author":"Kannan","year":"2011","journal-title":"J Postgrad Med"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s11096-011-9574-2","article-title":"Prevalence of potential drug\u2013drug interactions in bone marrow transplant patients","volume":"33","author":"Guastaldi","year":"2011","journal-title":"Int J Clin Pharm"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jnci\/djk130","article-title":"Potential drug interactions and duplicate prescriptions among cancer patients","volume":"99","author":"Riechelmann","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R22-20230918","first-page":"73","article-title":"Nephrotoxicity of aminoglycosides and cephalosporins in combination","volume":"8","author":"Rankin","year":"1989","journal-title":"Adverse Drug React Acute Poisoning Rev"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00228-010-0979-y","article-title":"Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database","volume":"67","author":"Strandell","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0022-5347(17)55813-9","article-title":"Adriamycin enhancement of cyclophosphamide-induced bladder injury","volume":"123","author":"Ershler","year":"1980","journal-title":"J Urol"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3565(25)25025-X","article-title":"Interactions between cyclophosphamide and doxorubicin metabolism in rats. II. Effect of cyclophosphamide on the aldoketoreductase system","volume":"237","author":"Dodion","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2165\/11538460-000000000-00000","article-title":"Risk of potential drug-drug interactions among Brazilian elderly","volume":"27","author":"Secoli","year":"2010","journal-title":"Drugs Aging"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201904000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:24:39Z","timestamp":1775298279000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201904000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001346","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}